Researchers report that changes in blood antibody profiles can signal the development of inflammatory bowel disease (IBD) up to 10 years before a formal diagnosis. The findings come from a large-scale study presented at UEG Week 2026 and focuses on immune responses that appear long before symptoms lead to clinical identification of IBD.
IBD includes Crohn’s disease and ulcerative colitis. While current care typically starts after symptoms emerge—by which point intestinal damage may already have occurred—both outlets describe how the immune system shows measurable “warning signals” well in advance. The research suggests antibody patterns could be used to identify people at elevated risk, potentially enabling earlier monitoring, timely evaluation, and, in the longer term, earlier intervention.
The sources differ mainly in emphasis: one highlights the prospect of new approaches to earlier risk detection and understanding how IBD may progress, while the other stresses the potential for predictive “warning signs” to improve the timing of diagnosis and treatment. Both agree the study identifies distinct immune patterns in advance of diagnosis.
